盆腔廓清术 (PE) 通常是选择性局部晚期和局部复发性结直肠癌（发病率较高）的唯一治疗选择。该手术接受开放式和腹腔镜手术。本研究旨在检查中国患者报告的 PE 后的结果 (PRO) 和健康相关的生活质量 (HRQoL)。总共 122 名入组参与者被要求在基线时完成 PRO。 PE 后 1、3、6、9 和 12 个月。 PRO 包括来自国家癌症研究所不良事件通用术语标准 (PRO-CTCAE) 的患者报告结果版本的七种症状。采用结直肠癌治疗功能评估（FACT-C）评估HRQoL。术后总体并发症率为41.0%。术后 1 个月，患者的身体和功能健康状况和 FACT-C 表现较差，然后逐渐恢复。术后 9 个月 FACT-C 评分恢复至基线。直到手术后 6 个月，社交和情感健康才出现恢复迹象，直到术后 12 个月才完全恢复到基线。直到术后 12 个月，失眠、焦虑、沮丧和悲伤（综合评分 >0）的症状发生率才较基线显着改善。PE 是局部晚期原发性和复发性结直肠癌的可行治疗选择。与身体状况相比，中国人群PE后的社交、心理和情绪恢复往往较慢。© 2024。外科肿瘤学会。

Pelvic exenteration (PE) is often the only curative treatment option for selected locally advanced and locally recurrent colorectal cancer associated with significant morbidity. Open and laparoscopic approaches were accepted for this procedure.This study aimed to examine the Chinese patient-reported outcomes (PROs) and health-related quality of life (HRQoL) after PE.A total of 122 enrolled participants were asked to complete PROs at baseline and 1, 3, 6, 9 and 12 months after PE. PROs included seven symptoms from the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). The HRQoL was assessed using the Functional Assessment of Cancer Therapy-Colorectal (FACT-C).The overall postoperative complication rate was 41.0%. Patients experienced lower physical and functional well-being and FACT-C 1 month after surgery, then gradually recovered. The FACT-C score returned to baseline 9 months after surgery. Social and emotional well-being did not show signs of recovery until 6 months after the surgical procedure, and did not fully return to baseline until 12 months post-surgery. Symptom rates of insomnia, anxiety, discouragement, and sadness (composite score >0) did not improve significantly from baseline until 12 months after surgery.PE is a feasible treatment choice for locally advanced primary and recurrent colorectal cancer. Social, psychological, and emotional recovery in the Chinese population after PE tends to be slower compared with the physical condition.© 2024. Society of Surgical Oncology.